ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis (Q39612149)
Jump to navigation
Jump to search
scientific article published on 27 December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis |
scientific article published on 27 December 2010 |
Statements
1 reference
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis (English)
1 reference
Yuji Sakuma
1 reference
Jun Tsunezumi
1 reference
Yoshiyasu Nakamura
1 reference
Mitsuyo Yoshihara
1 reference
Shoichi Matsukuma
1 reference
Shiro Koizume
1 reference
Yohei Miyagi
1 reference
27 December 2010
1 reference
1 reference
Identifiers
1 reference